EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 3.0

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study

Yue Fei, Zhihong Xie, Yuanyuan Luo, Xiaolan Yong, Na Li, Rong Huang, Xiaolin Du, Yijing Zhu, Dongmei Lan, Yang Qi, Gang Cheng, Quanren Wang und 1 weitere

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s500384 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Yue Fei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Jiangsu Hengrui Pharmaceuticals, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Renal Insufficiency. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsRenal InsufficiencyAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralDose-Response Relationship, DrugGlomerular Filtration Rate

Stichwörter der Autor:innen

chronic kidney diseasemineralocorticoid receptor antagonistpharmacokineticsrenal impairment

Substanzen

Mineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Clinical Research, Jiangsu Hengrui Pharmaceuticals, Shanghai, People's Republic of China.
  • Phase I Clinical Trial Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
  • Phase I Clinical Trial Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People's Republic of China.
  • Phase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, People's Republic of China.

ORCID-Profile: Kai Shen

Zitieren

APA

Fei, Y., Xie, Z., Luo, Y., Yong, X., Li, N., Huang, R., Du, X., Zhu, Y., Lan, D., Qi, Y., Cheng, G., Wang, Q., & Shen, K. (2025). Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s500384

Vancouver

Fei Y, Xie Z, Luo Y, Yong X, Li N, Huang R, et al. Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s500384

BibTeX
@article{Fei2025,
  author = {Fei, Yue and Xie, Zhihong and Luo, Yuanyuan and Yong, Xiaolan and Li, Na and Huang, Rong and Du, Xiaolin and Zhu, Yijing and Lan, Dongmei and Qi, Yang and Cheng, Gang and Wang, Quanren and Shen, Kai},
  title = {Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s500384}
}
Kostenlos starten →